ASRS ’24: PAVILION at 100 Weeks - Listen - New Retina Radio by

ASRS ’24: PAVILION at 100 Weeks

Listen now

Description

The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME. Plus, Dr. Chang offers her opinions on what it will take for retina specialists to trust the PDS now that the next-generation model has been released. Hear what she has to say in this one-on-one interview.

More Episodes

See all »

AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement

Are retina doctors seeing more retinal pathology following infection or vaccination? Or is there nothing to see here? Rahul Khurana, MD, joins us to discuss the findings of various health care database analyses seeking to clarify whether COVID infection or vaccination were linked to retinal...

Published 10/31/24

GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?

We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient...

Published 10/28/24

New Retina Radio by Eyetube

Published 10/28/24